A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy.

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Casopitant (Primary) ; Casopitant (Primary) ; Dexamethasone (Primary) ; Ondansetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 20 May 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 10 Dec 2009 Interim cardiac safety analysis results presented at the 32nd Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top